Liaoning Kangchen Pharmaceutical

Kangchen Pharmaceutical Industry has a rich product line focused on chronic kidney disease treatment using modernized traditional Chinese medicine. Its lead TCM drug has over 20 years of clinical use and serves more than one million patients. The company also produces MRI contrast agents that have broken multinational monopolies in China’s market segment. New pipeline includes microbubble-based diagnostic therapeutics integrating diagnosis and treatment ("theranostics"). Clinical results show efficacy in lowering creatinine/BUN levels, stabilizing renal function, delaying dialysis onset, improving anemia/calcium/phosphate balance in CKD patients.